U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C24H28N4O4.ClH
Molecular Weight 472.964
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMANOGREL HYDROCHLORIDE

SMILES

Cl.COC1=CC=CC(=C1)C(=O)NC2=CC(C3=CC=NN3C)=C(OCCN4CCOCC4)C=C2

InChI

InChIKey=APWHJJLFCMBWQT-UHFFFAOYSA-N
InChI=1S/C24H28N4O4.ClH/c1-27-22(8-9-25-27)21-17-19(26-24(29)18-4-3-5-20(16-18)30-2)6-7-23(21)32-15-12-28-10-13-31-14-11-28;/h3-9,16-17H,10-15H2,1-2H3,(H,26,29);1H

HIDE SMILES / InChI

Description

Temanogrel (also known as APD791) is an oral small molecule inverse agonist of the serotonin 2A (5-HT2A) receptor with potent activity on platelets and vascular smooth muscle. Temanogrel has been studied in phase I clinical trials in healthy subjects to assess its pharmacokinetics, pharmacodynamics, and safety. However, these studies were terminated because of the sponsor’s decision.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Sample Use Guides

In Vivo Use Guide
APD791 (temanogrel) (10 or 20 or 40) mg single dose
Route of Administration: Oral